BIOM starts Phase II prostate cancer trial

Biomira (BIOM; TSE:BRA) began a Phase II trial of its BLP25 vaccine to

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE